Greenleaf Trust decreased its position in Allergan PLC. (NYSE:AGN) by 2.1% during the second quarter, Holdings Channel reports. The firm owned 2,068 shares of the company’s stock after selling 45 shares during the period. Greenleaf Trust’s holdings in Allergan PLC. were worth $503,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Veritas Asset Management LLP purchased a new stake in Allergan PLC. during the first quarter worth $761,339,000. Edgewood Management LLC increased its stake in Allergan PLC. by 7.0% in the first quarter. Edgewood Management LLC now owns 2,704,211 shares of the company’s stock worth $646,090,000 after buying an additional 178,055 shares during the period. Epoch Investment Partners Inc. increased its stake in Allergan PLC. by 3.8% in the first quarter. Epoch Investment Partners Inc. now owns 2,013,415 shares of the company’s stock worth $481,045,000 after buying an additional 73,081 shares during the period. UBS Asset Management Americas Inc. increased its stake in Allergan PLC. by 0.3% in the first quarter. UBS Asset Management Americas Inc. now owns 1,995,281 shares of the company’s stock worth $476,713,000 after buying an additional 5,042 shares during the period. Finally, Blue Ridge Capital L.L.C. increased its stake in Allergan PLC. by 24.1% in the first quarter. Blue Ridge Capital L.L.C. now owns 1,909,900 shares of the company’s stock worth $456,313,000 after buying an additional 370,400 shares during the period. 84.77% of the stock is currently owned by institutional investors and hedge funds.

Shares of Allergan PLC. (NYSE AGN) traded down 1.34% on Thursday, hitting $234.77. The stock had a trading volume of 921,192 shares. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $256.80. The company has a 50 day moving average of $246.68 and a 200-day moving average of $238.04. The firm has a market capitalization of $78.69 billion, a P/E ratio of 7.15 and a beta of 1.16.

Allergan PLC. (NYSE:AGN) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The business had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.25%. The firm’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same quarter last year, the business posted $3.35 EPS. Equities analysts predict that Allergan PLC. will post $16.25 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be given a dividend of $0.70 per share. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.18%. Allergan PLC.’s dividend payout ratio is 9.95%.

ILLEGAL ACTIVITY WARNING: This article was first posted by Daily Political and is owned by of Daily Political. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/08/10/greenleaf-trust-sells-45-shares-of-allergan-plc-nyseagn.html.

AGN has been the topic of a number of recent research reports. BidaskClub downgraded Allergan PLC. from a “buy” rating to a “hold” rating in a research report on Wednesday. Citigroup Inc. reissued a “focus list” rating and set a $261.27 target price (up from $184.50) on shares of Allergan PLC. in a research report on Friday, April 21st. Deutsche Bank AG reissued a “buy” rating and set a $273.00 target price (up from $265.00) on shares of Allergan PLC. in a research report on Monday, July 17th. Goldman Sachs Group, Inc. (The) downgraded Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 target price on the stock. in a research report on Wednesday, May 10th. Finally, Royal Bank Of Canada lifted their target price on Allergan PLC. from $279.00 to $284.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 10th. Eight research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Allergan PLC. has an average rating of “Buy” and an average price target of $274.49.

In related news, Director Nesli Basgoz sold 1,889 shares of the stock in a transaction that occurred on Thursday, May 18th. The shares were sold at an average price of $220.45, for a total transaction of $416,430.05. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.36% of the company’s stock.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.